A 12‐week administration of 1 g of hesperidin combined with lifestyle correction could improve NAFLD‐related risk indicators by preventing NF‐κB activation and reducing hs‐CRP and TNF‐α, compared to lifestyle correction alone in patients with NAFLD. Here, TNF is linked to metabolic dysfunction-associated steatotic liver disease.